eLife, Journal Year: 2024, Volume and Issue: 13
Published: Sept. 20, 2024
Glycans play an important role in modulating the interactions between natural killer cells and antibodies to fight pathogens harmful cells.
Language: Английский
ImmunoHorizons, Journal Year: 2023, Volume and Issue: 7(12), P. 886 - 897
Published: Dec. 1, 2023
Abstract mAbs are highly indispensable tools for diagnostic, prophylactic, and therapeutic applications. The first technique, hybridoma technology, was based on fusion of B lymphocytes with myeloma cells, which resulted in generation single against a specific Ag. Along several novel alternative methods have been developed to improve mAb generation, ranging from electrofusion the discovery completely technologies such as cell immortalization; phage, yeast, bacterial, ribosome, mammalian display systems; DNA/RNA encoded Abs; technology; transgenic animals; artificial intelligence/machine learning. This commentary outlines evolution, methodology, advantages, limitations various production techniques. Furthermore, advent next-generation Ab single-chain variable fragments, nanobodies, bispecific Abs, Fc-engineered biosimilars, mimetics, Ab-drug conjugates, healthcare pharmaceutical sectors become resourceful develop treatments diseases cancer autoimmune infectious diseases.
Language: Английский
Citations
29
Polymers, Journal Year: 2023, Volume and Issue: 15(23), P. 4563 - 4563
Published: Nov. 28, 2023
Polymeric drug delivery technology, which allows for medicinal ingredients to enter a cell more easily, has advanced considerably in recent decades. Innovative medication strategies use biodegradable and bio-reducible polymers, progress the field been accelerated by future possible research applications. Natural polymers utilized polymeric systems include arginine, chitosan, dextrin, polysaccharides, poly(glycolic acid), poly(lactic hyaluronic acid. Additionally, poly(2-hydroxyethyl methacrylate), poly(N-isopropyl acrylamide), poly(ethylenimine), dendritic bioabsorbable as well biomimetic bio-related drug-free macromolecular therapies have employed delivery. Different synthetic natural biomaterials are clinical phase mitigate different diseases. Drug methods using becoming increasingly common pharmaceutical industry, with biocompatible copolymers dendrimers having helped cure cancer systems. This review discusses all above components how, combining biological approaches, micro- nano-drug can result revolutionary gene devices.
Language: Английский
Citations
27
Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(7), P. 104047 - 104047
Published: June 1, 2024
Language: Английский
Citations
8
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Nov. 14, 2024
Abstract In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge can be largely attributed to demonstration of distinct advantages offered by various mRNA molecules, alongside rapid advancements nucleic delivery systems. It is noteworthy that immunogenicity presents a double-edged sword. context immunotherapy, extra supplementation adjuvant generally required for induction robust immune responses. Conversely, non-immunotherapeutic scenarios, activation unwanted considering host tolerability high expression demand mRNA-encoded functional proteins. Herein, mainly focused on linear non-replicating mRNA, we overview preclinical clinical progress prospects medicines encompassing vaccines other therapeutics. We also highlight importance focusing host-specific variations, including age, gender, pathological condition, concurrent medication individual patient, maximized efficacy safety upon administration. Furthermore, deliberate potential challenges may encounter realm disease treatment, current endeavors improvement, as well application future advancements. Overall, this review aims present comprehensive understanding mRNA-based therapies while illuminating prospective development drugs.
Language: Английский
Citations
6
Molecular Biotechnology, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 2, 2024
Language: Английский
Citations
5
Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)
Published: Oct. 11, 2024
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable communicable diseases. Over the past few years, market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) 11.07% from 2024 (237.64 billion USD estimated at end 2023) 2033 (679.03 by 2033). Ever since advent hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine which further progressed into humanized fully human antibodies, reducing risk immunogenicity. Some benefits over conventional drugs include drastic reduction chances adverse reactions, interactions between drugs, targeting specific proteins. While very efficient, their higher production costs impede process commercialization. However, cost factor been improved developing biosimilar as affordable versions therapeutic antibodies. Along recent advancements innovations antibody engineering have helped will furtherly help design bio-better efficacy than ones. These novel mAb-based set revolutionize existing drug therapies wide diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights current fundamental landscape development applications key factors influencing future projections, advancement, incorporation such promising immunotherapeutic candidates confrontation approach against list rationalistic mentioning any limitations facing this field.
Language: Английский
Citations
4
Digital Chemical Engineering, Journal Year: 2025, Volume and Issue: unknown, P. 100211 - 100211
Published: Jan. 1, 2025
Language: Английский
Citations
0
Genomics & Informatics, Journal Year: 2025, Volume and Issue: 23(1)
Published: Jan. 20, 2025
Abstract Hepatocellular carcinoma (HCC) is one of the most common types primary liver cancer and remains a leading cause cancer-related deaths worldwide. While traditional approaches like surgical resection tyrosine kinase inhibitors struggle against tumor’s immune evasion, monoclonal antibody (mAb)-based immunotherapies have emerged as promising alternatives. Several therapeutic antibodies that counter immunosuppressive tumor microenvironment demonstrated efficacy in clinical trials, to FDA approvals for advanced HCC treatment. A crucial aspect advancing these therapies lies understanding structural interactions between their targets. Recent findings indicate mAbs bispecific (bsAbs) can target different, non-overlapping epitopes on checkpoints such PD-1 CTLA-4. This review delves into epitope-paratope structurally unresolved bsAbs, discusses potential combination based epitopes. By leveraging this unique feature, could enhance activation, reduce resistance, improve overall efficacy, marking new direction antibody-based immunotherapy HCC.
Language: Английский
Citations
0
Biochemical Society Transactions, Journal Year: 2025, Volume and Issue: 53(01)
Published: Feb. 7, 2025
NANOBODIES® (Nbs) have emerged as valuable tools across therapeutic, diagnostic, and industrial applications owing to their small size consequent ability bind unique epitopes inaccessible conventional antibodies. While Nbs retrieved from immune libraries normally possess sufficient affinity specificity for cognate antigens in the practical use case, multimerization will often increase functional via avidity effects. Therefore, rescue binding broaden targeting specificities, recent efforts focused on conjugating multiple Nb clones — of identical or antigen cognates together. In vivo vitro approaches, including flexible linkers, antibody domains, self-assembling coiled coils, chemical conjugation, self-clustering hydrophobic sequences, been employed produce multivalent multispecific constructs. Examples successful are diverse, ranging immunoassaying reagents virus-neutralizing moieties. This review aims recapitulate modalities while highlighting applications, advantages, drawbacks tied each method.
Language: Английский
Citations
0
Frontiers in Chemistry, Journal Year: 2025, Volume and Issue: 13
Published: Feb. 20, 2025
Biopharmaceuticals are increasingly utilised in the treatment of oncological, inflammatory, and autoimmune diseases, largely due to their exceptional specificity targeting antigens. However, structural complexity, heterogeneity, sensitivity pose crucial challenges production, purification, delivery. Charge heterogeneity analysis, a Critical Quality Attribute these biomolecules used Control, is often performed using separative analytical techniques such as imaged capillary Isoelectric Focusing (icIEF). Recognized gold standard by industry, icIEF leverages pH gradient provide high-resolution profiling charge variants biotherapeutics. In this review, critical experimental parameters for method development context biotherapeutic drug QC will be discussed. Key aspects, including sample preparation, properties, carrier ampholytes, stabilizers, detection examined, supported recent literature. Advances technology its expanding applications underline robustness, reproducibility, compliance with regulatory standards, affirming pivotal role ensuring identity consistency biological products.
Language: Английский
Citations
0